Acclerating The Characterization of Next Generation Biotherapeutics with Novel Ion Trapping and Alternative Fragmentation



Thursday, June 24, 2021 at 12pm EDT |11am CDT | 9am PDT

Register Free:

Event Overview:

Next generation protein therapeutics present great promise for treating some of today's most challenging diseases. Unfortunately, these next generation biologics (NGBs) such as multispecific antibodies, fusion proteins or recombinant vaccines exhibit additional levels of complexity beyond regular monoclonal antibody therapeutics. New instrument capabilities and fragmentation techniques in liquid chromatography tandem mass spectrometry (LC-MS/MS) hold the key for accelerating the development of NGBs and increasing their availability.

Here we will explore some of the new advancements of a novel LC-MS/MS Q-TOF instrument (ZenoTOF 7600 system, SCIEX) which include a new alternative fragmentation cell based on electron-activated dissociation (EAD) and an ion trap for increasing duty cycle. Furthermore, case studies will be presented to illustrate how these technologies are advancing the ability to fully characterize and understand risks to some of the most challenging critical quality attributes (CQAs) for these molecules.

Key Learning Objectives:

  • Learn from experts about the unique analytical challenges presented by next generation biotherapeutics.
  • Get a preview of the new technologies introduced by the ZenoTOF 7600 system.
  • Gain insight to how electron-activated dissociation (EAD) and the novel ion trap are enabling for robust, streamlined definition of CQAs for NGBs.
  • Learn about how SCIEX OS software and Protein Metrics Byos software work together to deliver a simple and highly efficient workflow for NGB characterization.


Andrew D. Mahan, Ph.D.
Principal Scientist/MS Group Leader, Cell & Developability Sciences
Janssen Pharmaceutical Companies of Johnson & Johnson

Andrew (Andy) received a BS in Biochemistry from Temple University (Philadelphia, PA) and MS in Analytical Chemistry from Drexel University (Philadelphia, PA) before completing his PhD in Analytical Chemistry from Drexel University. In his current role as the mass spectrometry group leader, Andy focuses on protein characterization by mass spectrometry and providing innovative mass spectrometry-based approaches to facilitate biologics discovery and development. Andy’s group provides analytical support to cell line development and manufacturing cell line groups to enable the pipeline of new molecules from Discovery to Development.

Andy is enthusiastic and passionate about mass spectrometry and its role in bringing new medicines to patients. His mission and focus is on the continuous improvement of the technique and the flawless execution of analytical methods to help the organizations and teams of which he is a part.

Register Free:

Related Content